AI News>Press Release
- Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
- Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
- DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
- Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
- DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
- Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
- Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
- KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
- Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
- Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
- Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
- Typhoon Recovery: U-Haul Offers 30 Days Free Storage across Alaska
- Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure
- BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
- FLAGSTAR BANK, N.A. ANNOUNCES COMPLETION OF HOLDING COMPANY REORGANIZATION
- StoneX Expands Wealth Management Offering for Latin American Clients
- GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
- STEP Energy Services Ltd. Agrees to $5.50 Per Share Take Private Transaction With Funds Advised by ARC Financial Corp.
- Grindr Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – GRND
- ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value As of September 2025
- Nabors Energy Transition Corp. II Announces Extension of Its Outside Date
- CCH Holdings Ltd Announces Full Exercise of Over-Allotment Option
- Univest Securities, LLC Announces Closing of $25 Million Registered Direct Offering for its Client UTime Limited (NASDAQ: WTO)
- Fury Files Technical Report for the Eau Claire Gold Project in Quebec
- GreenFirst Welcomes the Restart of Operations at One of Its Key Customers, Kap Paper Inc.
- Granite REIT Declares Distribution for October 2025
- LenderMAC Enters into Strategic Relationship with Ares to Expand Origination and Non-QM Capabilities
- FCPT Announces Acquisition of a Heartland Dental Property for $3.3 Million
- PFD, PFO, FFC, FLC and DFP Announce Dividends for November
- Gyrodyne Announces Agreement with Star Equity Fund
- Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
- VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARE
- Credicorp Ltd.: Credicorp's “3Q25 quiet period”
- TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
- Humankind Investments Announces Liquidation of the Humankind US Stock ETF
- Third Coast Bancshares, Inc. Wins SCI Transaction of the Year
- Bank of America Declares Preferred Stock Dividends Payable in November and December 2025
- Old Dominion Freight Line Releases 2024 Sustainability Report
- Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
- PINTEC's Subsidiary ZIITECH Makes Its Debut at Tech Week Singapore 2025
- FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
- GIBO Holdings Limited Announces Transfer to Nasdaq Capital Market
- Western Alliance Bank Enters Strategic Alliance with Clover Lending Group to Expand Financing Access for Active Adult Communities
- BROAD ARROW'S WYNN LAS VEGAS AUCTION FEATURES SOUGHT-AFTER CARS FOR EVERY COLLECTOR'S TASTE
- Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
- Suburban Propane with Girl Scouts of Northern New Jersey and the Women in Trucking Association Partner for "Trucks are for Girls: Fueling the Future" Event
- Citi Appointed as Depositary Bank for POMDOCTOR LIMITED's ADR Program
- Cushman & Wakefield Hires Tony Coskren and Brian Pinch in Boston to Lead Industrial Investment Sales Throughout New England